HK:1875 Stock Latest News
Company AnnouncementsBioDlink’s CDMO Surge and WuXi XDC Deal Reshape Growth Strategy2M ago1875
Company AnnouncementsBioDlink updates corporate logo while keeping shareholder arrangements unchanged2M ago1875
Company AnnouncementsBioDlink Sets August Board Meeting to Approve Interim 2026 Results3M ago1875
Company AnnouncementsBioDlink reshapes company secretarial team under HKEX waiver4M ago1875
Company AnnouncementsBioDlink Wins Unanimous Shareholder Backing for Board Mandates at AGM4M ago1875
Company AnnouncementsBioDlink Wins RMB19 Million Monoclonal Antibody Manufacturing Mandate from WuXi Biologics4M ago1875Company AnnouncementsBioDlink to Replace PwC with Deloitte as Auditor in Governance-Driven Shift5M ago1875
Company AnnouncementsBioDlink Calls 2026 AGM to Approve Accounts, Board Changes and Share Issue Mandate5M ago1875- Company AnnouncementsBioDlink sets pricing controls and payment terms for continuing connected deals5M ago1875
Company AnnouncementsBioDlink Flags No Undisclosed Issues Amid Share Volatility and Deepens WuXi XDC CDMO Ties5M ago1875
Company AnnouncementsBioDlink Sets Long-Term Connected Deals With WuXi XDC, Triggers Shareholder Oversight5M ago1875
Company AnnouncementsBioDlink Calls Hybrid EGM to Approve WuXi XDC CDMO Master Services Deal5M ago1875
Company AnnouncementsWUXI XDC Gains Majority Control of TOT BIOPHARM After Cash Offers Close7M ago1875- Company AnnouncementsBioDlink’s CDMO Shift Cushions Revenue Fall as ADC and Global Push Gain Traction7M ago1875
- Company AnnouncementsWUXI XDC Unit Secures Control of TOT BIOPHARM as Cash Offers Turn Unconditional7M ago1875
Company AnnouncementsWuxi XDC’s Cash Offer for TOT BIOPHARM Falls Short of Control Threshold, Offer Extended7M ago1875
Company AnnouncementsBioDlink Sets March Board Meeting to Approve 2025 Annual Results8M ago1875
